Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10487-10495

  Fan, Xin Juan ^a   Wan, Xiang Bo ^a   Fu, Xin Hui ^a   Wu, Pei Huang ^a   Chen, Dian Ke ^a   Wang, Pu Ning ^a   Jiang, Li ^a   Wang, Dao Hai ^a   Chen, Zhi Ting ^a   Huang, Yan ^a   Wang, Jian Ping ^a   Wang, Lei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Disease relapse; Phosphorylated p38; Prognostic biomarker; TNM staging

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84922394850     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2320-3     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Jessup JM, Gunderson LL, Greene FL, Washington MK, Compton CC, Sobin LH, et al. 2010 staging system for colon and rectal carcinoma. Ann Surg Oncol. 2011;18:1513-7.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030-47.
4. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16:102-8.
5. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-99.
6. Zlobec I, Vuong T, Hayashi S, Haegert D, Tornillo L, Terracciano L, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer. 2007;96:793-800.
7. Baynes RD, Gansert J. Kras mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther. 2009;16:554-61.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
9. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12.
10. Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol. 1996;8:402-11.
11. Crews CM, Erikson RL. Extracellular signals and reversible protein phosphorylation: what to make of it all. Cell. 1993;74:215-7.
12. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 2010;70:832-41.
13. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, et al. Prognostic significance of phosphorylated p38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004;100:499-506.
14. Hipp S, Berg D, Ergin B, Schuster T, Hapfelmeier A, Walch A, et al. Interaction of snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients. Virchows Archiv. 2010;457:705-13.
15. Chiu SJ, Chao JI, Lee YJ, Hsu TS. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol Lett. 2008;179:63-70.
16. Paillas S, Boissiere F, Bibeau F, Denouel A, Mollevi C, Causse A, et al. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res. 2011;71:1041-9.
17. de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias- Gonzalez L, Melgar-Rojas P, Galan-Moya EM, et al. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene. 2012;31:1073-85.
18. Fan XJ, Wan XB, Huang Y, Cai HM, Fu XH, Yang ZL, et al. Epithelial-mesenchymal transition biomarkers and support vector machine guided model in preoperatively predicting regional lymph node metastasis for rectal cancer. Br J Cancer. 2012;106:1735-41.
19. Wan XB, Zhao Y, Fan XJ, Cai HM, Zhang Y, Chen MY, et al. Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach. PLoS One. 2012;7:e31989.
20. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414-8.
21. Xu J, Wan XB, Huang XF, Chan KC, Hong MH, Wang LH, et al. Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. J Clin Oncol. 2010;28:5202-9.
22. Yu Y, Yin D, Hoque MO, Cao B, Jia Y, Yang Y, et al. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol. 2012;33:307-14.
23. Lee S, Song YA, Park YL, Cho SB, Lee WS, Lee JH, et al. Expression of kitenin in human colorectal cancer and its relation to tumor behavior and progression. Pathol Int. 2011;61:210-20.
24. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. P53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer cell. 2007;11:175-89.
25. Rudolf E, John S, Cervinka M. Irinotecan induces senescence and apoptosis in colonic cells in vitro. Toxicol Lett. 2012;214:1-8.
26. Grossmann I, de Bock GH, Meershoek-Klein Kranenbarg WM, van de Velde CJ, Wiggers T. Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. Eur J Surg Oncol. 2007;33:183-7.
27. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020-9.
28. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the mosaic trial. J Clin Oncol. 2009;27:3109-16.
29. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872-7.
30. Gunderson LL, Callister M, Marschke R, Young-Fadok T, Heppell J, Efron J. Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointes Cancer Res: GCR. 2008;2:25-33.
31. Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol. 2010;8:27.